Sign In
Buy ENVB
$1.98
-0.240 (-10.81%)
At Close: Jun 03, 2026
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003
08:00am, Tuesday, 02'nd Jun 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003
08:00am, Tuesday, 19'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
09:00am, Friday, 15'th May 2026
Enveric Biosciences (NASDAQ: ENVB) (âEnvericâ or the âCompanyâ), a biotechnology company advancing next-generation neuroplastogenic small molecules to
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026
08:00am, Friday, 15'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to addres
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders
08:00am, Wednesday, 13'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model
08:00am, Tuesday, 05'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors
07:33am, Tuesday, 28'th Apr 2026
Appointment strengthens Board with seasoned public company biotech executive following recent Nasdaq direct listing SARASOTA, Fla., April 28, 2026 /PRNewswire/ -- Lakewood-Amedex Biotherapeutics Inc.
What's Going On With Enveric Biosciences Stock On Friday?
02:13pm, Friday, 24'th Apr 2026
Enveric Biosciences, Inc (NASDAQ:ENVB) stock is trading higher on Friday after the U.S. Food and Drug Administration (FDA) accelerated action on psychedelics as treatments.
Enveric Biosciences to Participate in a Panel Discussion at Needham's Virtual Psychedelics Forum
08:00am, Tuesday, 21'st Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Stock Soars After Trump's Psychedelics Executive Order
03:26pm, Monday, 20'th Apr 2026
Enveric surged more than 92% in premarket trading as investors rushed into psychedelic‑focused biotech names following the administration's weekend directive. The move sparked a sector‑wide rally.
Enveric Biosciences Announces Closing of Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
06:28pm, Friday, 17'th Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
Enveric Biosciences Announces Up To $13.9 Million Private Placement Priced At-The-Market Under Nasdaq Rules
08:00pm, Thursday, 16'th Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics t
Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates
08:00am, Tuesday, 31'st Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025
05:40pm, Friday, 27'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to addres
Enveric Biosciences Announces Registration of Five Trademarks
08:00am, Wednesday, 18'th Mar 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to addr
